Zachary L. Bercu, MD, RPVI, FSIR, explains how the Liberty endovascular robotic system works from the operator’s perspective and what went into becoming its first adopting site.
|Articles|May 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 5
- Volume 15
- Issue 5
FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib
FDA Grants Orphan Drug Status for Cephalon's Lestaurtinib
Advertisement
FRAZER, PennsylvaniaThe FDA has granted orphan drug status to Cephalon, Inc.'s lestaurtinib (CEP-701) for acute myeloid leukemia (AML). The oral compound inhibits several tyrosine kinases including FLT-3 and TrkA. It is in phase II/III trials for AML patients at first relapse who have a FLT-3 activating mutation.
Articles in this issue
over 20 years ago
Genentech Files sBLA for Avastin for First-Line NSCLC Treatmentover 20 years ago
RFA Effective for Single, Small Hepatocellular Carcinomaover 20 years ago
New Imaging, ChemoRT Recommendations From NCCNover 20 years ago
Panitumumab Improves PFS in Advanced Colon Caover 20 years ago
Studies Question Watchful Waiting for Some Prostate Ca Ptsover 20 years ago
Growing Evidence Supports Stem Cell Hypothesis of Cancerover 20 years ago
FDA Approves New Every-3-Week Dosing for Aranespover 20 years ago
Telephone Often Delivers News of Breast Cancer Diagnosisover 20 years ago
IND Submitted for CYT-500Advertisement
Related to this article
Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.
Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with HIV-associated lymphoma.
Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.
Melody Rasouli, MD, MBA, FACOG, discusses oncofertility gaps at NCI-designated cancer centers and ways to speed fertility referrals for patients.
Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.
In a phase 2 trial, berzosertib/carboplatin produced a 0% overall response rate vs 15% with docetaxel/carboplatin in heavily pretreated metastatic CRPC.
Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma
2
How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?
3
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
4
Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer
5